Vaccination advisory group may consider allowing Corbevax as a booster dose

Permitting Cobavax as a booster for those who are fully vaccinated against COVID-19 with Covashield or Covaxin is likely to be considered by the NTAGI (National Technical Advisory Group on Immunization), which will meet on Tuesday.

The Drugs Controller General of India (DCGI) on June 4 approved Corbevax as a precautionary dose for people aged 18 years and above. India's first indigenously developed RBD protein subunit vaccine Corbevax is currently being used to vaccinate children in the age group of 12 to 14 years.

The government advisory panel is also expected to review trial data for the quadrivalent human papillomavirus (qHPV) vaccine developed by the country's first Serum Institute of India against cervical cancer.

"NTAGI will discuss allowing Corbevax, which has been approved by DCGI as a booster for those fully vaccinated with Covishield or Covaxin," said a source.